Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Michael A. Nauck, Murray W. Stewart, Christopher Perkins, Angela Jones-Leone, Fred Yang, Caroline Perry, Rickey R. Reinhardt, Marc Rendell

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise'. Together they form a unique fingerprint.

Medicine & Life Sciences